Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT04801732 Completed - Clinical trials for Shoulder Impingement Syndrome

The Effect of Thoracic Mulligan Mobilization on Sub-acromial Impingement Syndrome

SAIS
Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This study was conducted to investigate the effect of mulligan thoracic sustained natural apophyseal glide on patients diagnosed as sub acromial impingement syndrome and its effect on shoulder range of motion, pain, function and disability of affected shoulder joint and size of sub acromial space, Half of the patients will treated with traditional treatment and mulligan thoracic SNAGS technique, while the other half will treated with traditional treatment only.

NCT ID: NCT04798911 Completed - Sjögren's Syndrome Clinical Trials

SS-INQ Information Needs Questionnaire in Sjögren's Syndrome

SS-INQ
Start date: October 12, 2018
Phase:
Study type: Observational

Patients with some long-standing rheumatic diseases have stated that they want to be fully informed about their disease as they find it 'more scary not to know' about possible complications and consequences. Patients who have the information they want about their disease can fully take part in decisions about their own health creating a partnership with their doctor. Sjögren's Syndrome (SS) is a multi-system, long-standing rheumatic disease that has a negative impact on the daily life of patients. A common presentation of this disease is dry mouth, which can make talking, eating and swallowing more difficult. Project aims: We aim to ask patients with SS what information they think it would be important to know about SS. We plan to create a questionnaire that can be used by doctors to help deliver the right information to patients at hospital visits. Timescale: This project will take 36 months to complete. Clinical relevance: This questionnaire could be used in daily practice. It could help patients cope with their disease, take part in treatment decision and reduced uncertainty and distress.

NCT ID: NCT04797819 Completed - Clinical trials for Acute Coronary Syndrome

Serum Soluble ST2 and Plaque Vulnerability in Patients With Acute Coronary Syndrome

Start date: January 1, 2019
Phase:
Study type: Observational

This study aimed to assess the association between serum sST2 level and plaque vulnerability in ACS patients. It is hypothesized that serum sST2 level may be related to plaque components and closely associated with plaque vulnerability.

NCT ID: NCT04795908 Completed - Tourette Syndrome Clinical Trials

Combined CBIT and rTMS to Improve Tourette's Syndrome

STOP-TIC
Start date: December 17, 2021
Phase: N/A
Study type: Interventional

The investigator will apply 16 sessions of repetitive transcranial magnetic stimulation (rTMS) over 4 consecutive days for adult patients suffering from Tourette's Syndrome. Following rTMS, patients will undergo 8 sessions of Comprehensive Behavioral Intervention for Tics (CBIT) over 10 weeks via telemedicine. Clinical improvement in tic severity will be the primary outcome measure. Secondary outcome measures including underlying physiological effects will be measured via functional magnetic resonance imaginge (fMRI), high-density electroencephalograhy (HD-EEG), and TMS.

NCT ID: NCT04794933 Completed - Clinical trials for Subacromial Impingement Syndrome

PNF in Subacromial Impingement Syndrome

Start date: December 2013
Phase: N/A
Study type: Interventional

Although proprioceptive neuromuscular facilitation (PNF) techniques have been used in the treatment of different shoulder problems, PNF techniques in scapular and upper trunk patterns with extremity pattern have not been considered as a possible option for the treatment of Subacromial Impingement Syndrome (SIS). The aim of this study was to evaluate the effects of different PNF patterns in SIS.

NCT ID: NCT04794413 Completed - Tourette Syndrome Clinical Trials

Pimavanserin Treatment in TS

Start date: November 12, 2018
Phase: Early Phase 1
Study type: Interventional

This research study is determining if a drug called Pimavanserin if safe and effective in the treatment of the symptoms of Tourette Syndrome. Pimavanserin is an investigational drug for Tourette Syndrome, which means it has not been approved by the United States Food and Drug Administration (FDA) to treat Tourette Syndrome. Pimavanserin has been approved by the FDA as a treatment for hallucinations in Parkinson's Disease. It is currently marketed under the name NUPLAZID (pimavanserin) capsules by Acadia Pharmaceuticals.

NCT ID: NCT04792047 Completed - Clinical trials for Acute Coronary Syndrome

Pericoronary Fat Attenuation Index and High-risk Plaque in Patients With Acute Coronary Syndrome

Start date: January 1, 2019
Phase:
Study type: Observational

This study aimed to investigate the relationship between CCTA-based pericoronary inflammation and plaque features as well as local immune-inflammatory biomarkers in ACS patients. It is hypothesized that perivascular FAI might serve as a reliable sensor of coronary immune-inflammatory disorder, and closely related to the plaque vulnerability.

NCT ID: NCT04791397 Completed - Metabolic Syndrome Clinical Trials

Evaluation of the Effect of IHHT on Vascular Stiffness and Elasticity of the Liver Tissue in Patients With MS.

Start date: April 10, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to assess the effect of interval hypoxy-hyperoxic training (IHHT) on the arterial stiffness and elasticity of the liver tissue in patients with metabolic syndrome and on other components of the metabolic syndrome, and the possibility of their reversible recovery after training.

NCT ID: NCT04787861 Completed - Down Syndrome Clinical Trials

Motorized Movement Therapy & Pulmonary Functions in Down Syndrome

Start date: December 17, 2018
Phase: N/A
Study type: Interventional

To investigate the effects of the addition of motorized movement therapy versus conventional chest physiotherapy alone on pulmonary functions, exercise capacity, and endurance in children with Down Syndrome

NCT ID: NCT04785573 Completed - Metabolic Syndrome Clinical Trials

The Effect of Mastiha Oil in Metabolic Syndrome

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

Mastiha Oil is a 100% natural product of the Mediterranean, extracted from the resin of Mastiha. Over 90 compounds have been identified in Mastiha oil, with monoterpenes exhibiting favorable effects in regulating mechanisms of oxidative stress and inflammation. The aim of this study is to determine the effect of Mastiha oil in adults with Metabolic Syndrome. 90 participants will be allocated to two groups, (45 in intervention group and 45 in control group). Mastiha oil will be provided in the form of soft gel capsules to the intervention group, whereas the control group will not consume the capsules. Both groups will receive standard nutritional counselling. The intervention will last 3 months. The effects of the intervention will be evaluated via clinical and laboratory markers.